Cargando…
New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans
OBJECTIVE: Prokineticin 2 (PROK2) is a hypothalamic neuropeptide that plays a critical role in the rhythmicity of physiological functions and inhibits food intake. PROK2 is also expressed in the main olfactory bulb (MOB) as an essential factor for neuro-and morphogenesis. Since the MOB was shown to...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812023/ https://www.ncbi.nlm.nih.gov/pubmed/31668389 http://dx.doi.org/10.1016/j.molmet.2019.08.016 |
_version_ | 1783462587216691200 |
---|---|
author | Mortreux, Marie Foppen, Ewout Denis, Raphaël G. Montaner, Mireia Kassis, Nadim Denom, Jessica Vincent, Mylène Fumeron, Frédéric Kujawski-Lafourcade, Margaux Andréelli, Fabrizio Balkau, Beverley Marre, Michel Roussel, Ronan Magnan, Christophe Gurden, Hirac Migrenne-Li, Stéphanie |
author_facet | Mortreux, Marie Foppen, Ewout Denis, Raphaël G. Montaner, Mireia Kassis, Nadim Denom, Jessica Vincent, Mylène Fumeron, Frédéric Kujawski-Lafourcade, Margaux Andréelli, Fabrizio Balkau, Beverley Marre, Michel Roussel, Ronan Magnan, Christophe Gurden, Hirac Migrenne-Li, Stéphanie |
author_sort | Mortreux, Marie |
collection | PubMed |
description | OBJECTIVE: Prokineticin 2 (PROK2) is a hypothalamic neuropeptide that plays a critical role in the rhythmicity of physiological functions and inhibits food intake. PROK2 is also expressed in the main olfactory bulb (MOB) as an essential factor for neuro-and morphogenesis. Since the MOB was shown to be strongly involved in eating behavior, we hypothesized that PROK2 could be a new target in the regulation of food intake and energy homeostasis, through its effects in the MOB. We also asked whether PROK2 could be associated with the pathophysiology of obesity, the metabolic syndrome (MetS), and type 2 diabetes (T2D) in humans. METHODS: We assessed in wild type mice whether the expression of Prok2 in the MOB is dependent on the nutritional status. We measured the effect of human recombinant PROK2 (rPROK2) acute injection in the MOB on food intake and olfactory behavior. Then, using a lentivirus expressing Prok2-shRNA, we studied the effects of Prok2 underexpression in the MOB on feeding behavior and glucose metabolism. Metabolic parameters and meal pattern were determined using calorimetric cages. In vivo 2-deoxyglucose uptake measurements were performed in mice after intraperitoneally insulin injection. Plasmatic PROK2 dosages and genetic associations studies were carried out respectively on 148 and more than 4000 participants from the D.E.S.I.R. (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort. RESULTS: Our findings showed that fasting in mice reduced Prok2 expression in the MOB. Acute injection of rPROK2 in the MOB significantly decreased food intake whereas Prok2-shRNA injection resulted in a higher dietary consumption characterized by increased feeding frequency and decreased meal size. Additionally, Prok2 underexpression in the MOB induced insulin resistance compared to scrambled shRNA-injected mice. In the human D.E.S.I.R. cohort, we found a significantly lower mean concentration of plasma PROK2 in people with T2D than in those with normoglycemia. Interestingly, this decrease was no longer significant when adjusted for Body Mass Index (BMI) or calorie intake, suggesting that the association between plasma PROK2 and diabetes is mediated, at least partly, by BMI and feeding behavior in humans. Moreover, common Single Nucleotide Polymorphisms (SNPs) in PROK2 gene were genotyped and associated with incident T2D or impaired fasting glycemia (IFG), MetS, and obesity. CONCLUSIONS: Our data highlight PROK2 as a new target in the MOB that links olfaction with eating behavior and energy homeostasis. In humans, plasma PROK2 is negatively correlated with T2D, BMI, and energy intake, and PROK2 genetic variants are associated with incident hyperglycemia (T2D/IFG), the MetS and obesity. |
format | Online Article Text |
id | pubmed-6812023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-68120232019-10-30 New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans Mortreux, Marie Foppen, Ewout Denis, Raphaël G. Montaner, Mireia Kassis, Nadim Denom, Jessica Vincent, Mylène Fumeron, Frédéric Kujawski-Lafourcade, Margaux Andréelli, Fabrizio Balkau, Beverley Marre, Michel Roussel, Ronan Magnan, Christophe Gurden, Hirac Migrenne-Li, Stéphanie Mol Metab Original Article OBJECTIVE: Prokineticin 2 (PROK2) is a hypothalamic neuropeptide that plays a critical role in the rhythmicity of physiological functions and inhibits food intake. PROK2 is also expressed in the main olfactory bulb (MOB) as an essential factor for neuro-and morphogenesis. Since the MOB was shown to be strongly involved in eating behavior, we hypothesized that PROK2 could be a new target in the regulation of food intake and energy homeostasis, through its effects in the MOB. We also asked whether PROK2 could be associated with the pathophysiology of obesity, the metabolic syndrome (MetS), and type 2 diabetes (T2D) in humans. METHODS: We assessed in wild type mice whether the expression of Prok2 in the MOB is dependent on the nutritional status. We measured the effect of human recombinant PROK2 (rPROK2) acute injection in the MOB on food intake and olfactory behavior. Then, using a lentivirus expressing Prok2-shRNA, we studied the effects of Prok2 underexpression in the MOB on feeding behavior and glucose metabolism. Metabolic parameters and meal pattern were determined using calorimetric cages. In vivo 2-deoxyglucose uptake measurements were performed in mice after intraperitoneally insulin injection. Plasmatic PROK2 dosages and genetic associations studies were carried out respectively on 148 and more than 4000 participants from the D.E.S.I.R. (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort. RESULTS: Our findings showed that fasting in mice reduced Prok2 expression in the MOB. Acute injection of rPROK2 in the MOB significantly decreased food intake whereas Prok2-shRNA injection resulted in a higher dietary consumption characterized by increased feeding frequency and decreased meal size. Additionally, Prok2 underexpression in the MOB induced insulin resistance compared to scrambled shRNA-injected mice. In the human D.E.S.I.R. cohort, we found a significantly lower mean concentration of plasma PROK2 in people with T2D than in those with normoglycemia. Interestingly, this decrease was no longer significant when adjusted for Body Mass Index (BMI) or calorie intake, suggesting that the association between plasma PROK2 and diabetes is mediated, at least partly, by BMI and feeding behavior in humans. Moreover, common Single Nucleotide Polymorphisms (SNPs) in PROK2 gene were genotyped and associated with incident T2D or impaired fasting glycemia (IFG), MetS, and obesity. CONCLUSIONS: Our data highlight PROK2 as a new target in the MOB that links olfaction with eating behavior and energy homeostasis. In humans, plasma PROK2 is negatively correlated with T2D, BMI, and energy intake, and PROK2 genetic variants are associated with incident hyperglycemia (T2D/IFG), the MetS and obesity. Elsevier 2019-08-28 /pmc/articles/PMC6812023/ /pubmed/31668389 http://dx.doi.org/10.1016/j.molmet.2019.08.016 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Mortreux, Marie Foppen, Ewout Denis, Raphaël G. Montaner, Mireia Kassis, Nadim Denom, Jessica Vincent, Mylène Fumeron, Frédéric Kujawski-Lafourcade, Margaux Andréelli, Fabrizio Balkau, Beverley Marre, Michel Roussel, Ronan Magnan, Christophe Gurden, Hirac Migrenne-Li, Stéphanie New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans |
title | New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans |
title_full | New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans |
title_fullStr | New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans |
title_full_unstemmed | New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans |
title_short | New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans |
title_sort | new roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: studies in mice and humans |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812023/ https://www.ncbi.nlm.nih.gov/pubmed/31668389 http://dx.doi.org/10.1016/j.molmet.2019.08.016 |
work_keys_str_mv | AT mortreuxmarie newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT foppenewout newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT denisraphaelg newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT montanermireia newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT kassisnadim newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT denomjessica newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT vincentmylene newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT fumeronfrederic newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT kujawskilafourcademargaux newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT andreellifabrizio newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT balkaubeverley newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT marremichel newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT rousselronan newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT magnanchristophe newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT gurdenhirac newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans AT migrennelistephanie newrolesforprokineticin2infeedingbehaviorinsulinresistanceandtype2diabetesstudiesinmiceandhumans |